Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | FGF2 | P09038 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29009049 | 0.80 | MGLL (0.67) | MGMTMGLLABCG2ALDH1A1CRBN | |
| SCHEMBL26349168 | 0.80 | MGMT (0.43) | MGMTGAAMGLLPOLBABCG2 | |
| SCHEMBL27252888 | 0.80 | MGLL (0.67) | MGMTMGLLABCG2ALDH1A1CRBN | |
| SCHEMBL25495610 | 0.80 | MGLL (0.67) | MGMTMGLLABCG2ALDH1A1CRBN | |
| SCHEMBL14645284 | 0.80 | MGMT (0.46) | MGMTGAAMGLLABCG2CRBN | |
| SCHEMBL13695964 | 0.80 | MGLL (0.67) | MGMTMGLLABCG2ALDH1A1CRBN | |
| SCHEMBL25495612 | 0.79 | MGMT (0.42) | MGMTMGLLABCG2 | |
| SCHEMBL21117957 | 0.77 | GAA (0.33) | MGMTGAAPOLBALDH1A1CRBN | |
| SCHEMBL17262434 | 0.77 | MGMT (0.40) | MGMTGAAMGLLABCG2 | |
| SCHEMBL18212282 | 0.77 | MGMT (0.40) | MGMTGAAMGLLABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024005461-A1 | NOVEL LINKER COMPOUND AND LIGAND-DRUG CONJUGATE THEREFOR | 주식회사 트리오어 | 2024-01-04 | — | — | WO | disclosed |
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | SIGILON THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | SIGILON THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| EP-4192468-A2 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | Sigilon Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | CYP3A43, CYP2C9, CYP2C19 | MGMT 2441/4885GAA 294/4885MGLL 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.